Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Exela Technologies, Inc.XELA · Entity 76832 | Director | August 16, 2022 | August 18, 2022 |
| XBP Global Holdings, Inc.XBP · Entity 7388 | Director | February 13, 2025 | February 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Exela Technologies, Inc.
Report date August 16, 2022 · Filed August 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-08-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-16 · Exercise / conversion · Disposed 6,250 · Balance 0 F2: Each restricted stock unit represents the right to receive, following vesting, one share of Common Stock, which may be settled in shares of Common Stock or cash, as elected by the Compensation Committee of the Board of Directors of the Company. F1: On December 31, 2021, the reporting person was granted 6,250 restricted stock units in accordance with the Company's Amended and Restated Stock 2018 Incentive Plan ("Plan") that were settled in January 2022. The Plan was approved by the stockholders of the Company at the Company's 2021 annual meeting held December 31, 2021. Subsequent to such approval, a lawsuit was filed against the Company alleging that the Company did not properly count the broker non-votes on such matter, and that as a result the Plan was not properly approved at the 2021 annual meeting. The Company decided to re-submit the Plan to its stockholders for re-approvals at its 2022 annual meeting rather than incurring the expense of pursuing litigation. Following the re-approval of the amended and restated Plan at the 2022 annual meeting, the Compensation Committee determined, that the restricted stock units be settled in cash effective August 16, 2022. F3: The number of shares reported in this Form 4 account for the one-for-twenty Reverse Stock Split effected by the Issuer on July 26, 2022. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise were entitled to receive fractional shares of Common Stock received cash (without interest or deduction) from the Corporation's transfer agent in lieu of such fractional share interests. |
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 4,510 |
Reported balance
Holding disclosure · report date 2022-08-16 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 4,510 F3: The number of shares reported in this Form 4 account for the one-for-twenty Reverse Stock Split effected by the Issuer on July 26, 2022. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise were entitled to receive fractional shares of Common Stock received cash (without interest or deduction) from the Corporation's transfer agent in lieu of such fractional share interests. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 31, 2021, the reporting person was granted 6,250 restricted stock units in accordance with the Company's Amended and Restated Stock 2018 Incentive Plan ("Plan") that were settled in January 2022. The Plan was approved by the stockholders of the Company at the Company's 2021 annual meeting held December 31, 2021. Subsequent to such approval, a lawsuit was filed against the Company alleging that the Company did not properly count the broker non-votes on such matter, and that as a result the Plan was not properly approved at the 2021 annual meeting. The Company decided to re-submit the Plan to its stockholders for re-approvals at its 2022 annual meeting rather than incurring the expense of pursuing litigation. Following the re-approval of the amended and restated Plan at the 2022 annual meeting, the Compensation Committee determined, that the restricted stock units be settled in cash effective August 16, 2022.
F2: Each restricted stock unit represents the right to receive, following vesting, one share of Common Stock, which may be settled in shares of Common Stock or cash, as elected by the Compensation Committee of the Board of Directors of the Company.
F3: The number of shares reported in this Form 4 account for the one-for-twenty Reverse Stock Split effected by the Issuer on July 26, 2022. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise were entitled to receive fractional shares of Common Stock received cash (without interest or deduction) from the Corporation's transfer agent in lieu of such fractional share interests.
XBP Global Holdings, Inc.
Report date February 13, 2025 · Filed February 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 184,857 |
Reported balance
After 2025-02-13 transaction · row 1
1 source rowRow 1 · 2025-02-13 · Grant · Acquired 119,436 · Balance 184,857 F1: Represents Restricted Stock Units ("RSUs") issued to the Reporting Person under the XBP Europe Holdings, Inc. 2024 Stock Incentive Plan (the "Plan"). The RSUs granted under the Plan will vest in full on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units ("RSUs") issued to the Reporting Person under the XBP Europe Holdings, Inc. 2024 Stock Incentive Plan (the "Plan"). The RSUs granted under the Plan will vest in full on the first anniversary of the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Express Scripts Holding Co.
Report date December 20, 2018 · Filed December 21, 2018
Section 16 reporting ended · disclosed 2018-12-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 1
1 source rowRow 1 · 2018-12-20 · Disposition to issuer · Disposed 46,219.16 · Balance 0 F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a unit with respect to common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.05 · Expires 2019-02-27 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-12-20 · Disposition to issuer · Disposed 1,964 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.54 · Expires 2019-05-15 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-12-20 · Disposition to issuer · Disposed 1,547 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.17 · Expires 2020-03-06 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-12-20 · Disposition to issuer · Disposed 4,280 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.15 · Expires 2021-03-05 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-12-20 · Disposition to issuer · Disposed 5,946 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.83 · Expires 2025-03-04 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-12-20 · Disposition to issuer · Disposed 5,626 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $86.82 · Expires 2025-12-01 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-12-20 · Disposition to issuer · Disposed 34,909 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.57 · Expires 2026-03-09 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-12-20 · Disposition to issuer · Disposed 48,735 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.62 · Expires 2027-03-08 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-12-20 · Disposition to issuer · Disposed 47,254 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Phantom Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-12-20 · Disposition to issuer · Disposed 460.815 · Balance 0 F4: Phantom Stock Unit credited under the Company's Executive Deferred Compensation Plan. F5: Upon distribution, each phantom stock unit would have converted into one share of the Issuer's common stock. F6: Pursuant to the Merger Agreement, upon closing of the Merger, each phantom stock unit was converted into a stock unit relating to the common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F7: Basic Company Credit by the Issuer to Reporting Person's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a unit with respect to common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.
F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted.
F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.
F4: Phantom Stock Unit credited under the Company's Executive Deferred Compensation Plan.
F5: Upon distribution, each phantom stock unit would have converted into one share of the Issuer's common stock.
F6: Pursuant to the Merger Agreement, upon closing of the Merger, each phantom stock unit was converted into a stock unit relating to the common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.
F7: Basic Company Credit by the Issuer to Reporting Person's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2025 Filed Feb 18, 2025 20:29 UTC | XBP Global Holdings, Inc. XBP · Entity 7388 | GrantCommon Stock, par value $0.0001 per share | 119,436 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-002747 · form4.xml · nonDerivative · entry 1 Akins Martin P. · CIK 0001655236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,857 F1 · shares: Represents Restricted Stock Units ("RSUs") issued to the Reporting Person under the XBP Europe Holdings, Inc. 2024 Stock Incentive Plan (the "Plan"). The RSUs granted under the Plan will vest in full on the first anniversary of the grant date. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 21:30 UTC | XBP Global Holdings, Inc. XBP · Entity 7388 | GrantCommon Stock, par value $0.0001 per share | 65,421 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-072477 · tm2417344-1_4seq1.xml · nonDerivative · entry 1 Akins Martin P. · CIK 0001655236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,421 F1 · shares: Represents Restricted Stock Units ("RSUs") issued to the Reporting Person under the XBP Europe Holdings Inc. 2024 Stock Incentive Plan (the "Plan"). Although RSU's granted under the Plan generally require a minimum of one year to vest, the RSU's disclosed on this Form 4 will vest on January 1, 2025, as allowed for under the Plan's exception for allowing up to 5% of the aggregate number of common shares that may be delivered pursuant to awards granted under the Plan to have a vesting period of less than one year. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 21:52 UTC | Exela Technologies, Inc. XELA · Entity 76832 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-092706 · tm2223344-6_4seq1.xml · derivative · entry 2 Akins Martin P. · CIK 0001655236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of Common Stock, which may be settled in shares of Common Stock or cash, as elected by the Compensation Committee of the Board of Directors of the Company. F1 · kind: On December 31, 2021, the reporting person was granted 6,250 restricted stock units in accordance with the Company's Amended and Restated Stock 2018 Incentive Plan ("Plan") that were settled in January 2022. The Plan was approved by the stockholders of the Company at the Company's 2021 annual meeting held December 31, 2021. Subsequent to such approval, a lawsuit was filed against the Company alleging that the Company did not properly count the broker non-votes on such matter, and that as a result the Plan was not properly approved at the 2021 annual meeting. The Company decided to re-submit the Plan to its stockholders for re-approvals at its 2022 annual meeting rather than incurring the expense of pursuing litigation. Following the re-approval of the amended and restated Plan at the 2022 annual meeting, the Compensation Committee determined, that the restricted stock units be settled in cash effective August 16, 2022. F3 · shares: The number of shares reported in this Form 4 account for the one-for-twenty Reverse Stock Split effected by the Issuer on July 26, 2022. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise were entitled to receive fractional shares of Common Stock received cash (without interest or deduction) from the Corporation's transfer agent in lieu of such fractional share interests. F1 · derivative.exercise_date: On December 31, 2021, the reporting person was granted 6,250 restricted stock units in accordance with the Company's Amended and Restated Stock 2018 Incentive Plan ("Plan") that were settled in January 2022. The Plan was approved by the stockholders of the Company at the Company's 2021 annual meeting held December 31, 2021. Subsequent to such approval, a lawsuit was filed against the Company alleging that the Company did not properly count the broker non-votes on such matter, and that as a result the Plan was not properly approved at the 2021 annual meeting. The Company decided to re-submit the Plan to its stockholders for re-approvals at its 2022 annual meeting rather than incurring the expense of pursuing litigation. Following the re-approval of the amended and restated Plan at the 2022 annual meeting, the Compensation Committee determined, that the restricted stock units be settled in cash effective August 16, 2022. F1 · derivative.expiration_date: On December 31, 2021, the reporting person was granted 6,250 restricted stock units in accordance with the Company's Amended and Restated Stock 2018 Incentive Plan ("Plan") that were settled in January 2022. The Plan was approved by the stockholders of the Company at the Company's 2021 annual meeting held December 31, 2021. Subsequent to such approval, a lawsuit was filed against the Company alleging that the Company did not properly count the broker non-votes on such matter, and that as a result the Plan was not properly approved at the 2021 annual meeting. The Company decided to re-submit the Plan to its stockholders for re-approvals at its 2022 annual meeting rather than incurring the expense of pursuing litigation. Following the re-approval of the amended and restated Plan at the 2022 annual meeting, the Compensation Committee determined, that the restricted stock units be settled in cash effective August 16, 2022. F3 · derivative.underlying_shares: The number of shares reported in this Form 4 account for the one-for-twenty Reverse Stock Split effected by the Issuer on July 26, 2022. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise were entitled to receive fractional shares of Common Stock received cash (without interest or deduction) from the Corporation's transfer agent in lieu of such fractional share interests. Read SEC document |
| June 27, 2022 Filed Jun 29, 2022 20:58 UTC | Exela Technologies, Inc. XELA · Entity 76832 | Exercise / conversionRestricted Stock Units · Derivative | 13,228 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-075923 · tm2220064-2_4seq1.xml · derivative · entry 3 Akins Martin P. · CIK 0001655236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,228 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of Common Stock, which may be settled in shares of Common Stock or cash, as elected by the Compensation Committee of the Board of Directors of the Company. F2 · price: Each restricted stock unit represents the right to receive, following vesting, one share of Common Stock, which may be settled in shares of Common Stock or cash, as elected by the Compensation Committee of the Board of Directors of the Company. F3 · derivative.exercise_date: On August 13, 2019, the reporting person was granted 119,047 restricted stock units (before taking into account the one-for-three Reverse Stock Split effected by the Company on January 25, 2021) as non-employee director equity compensation pursuant to the terms and conditions of the Company's Director Compensation Policy and 2018 Stock Incentive Plan. The restricted stock units vested in equal installments at each of the 2020, 2021 and 2022 annual meetings. F3 · derivative.expiration_date: On August 13, 2019, the reporting person was granted 119,047 restricted stock units (before taking into account the one-for-three Reverse Stock Split effected by the Company on January 25, 2021) as non-employee director equity compensation pursuant to the terms and conditions of the Company's Director Compensation Policy and 2018 Stock Incentive Plan. The restricted stock units vested in equal installments at each of the 2020, 2021 and 2022 annual meetings. Read SEC document |
| June 27, 2022 Filed Jun 29, 2022 20:58 UTC | Exela Technologies, Inc. XELA · Entity 76832 | Exercise / conversionCommon Stock, par value $0.0001 per share | 13,228 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-075923 · tm2220064-2_4seq1.xml · nonDerivative · entry 1 Akins Martin P. · CIK 0001655236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 21:49 UTC | Exela Technologies, Inc. XELA · Entity 76832 | OtherRestricted Stock Units · Derivative | 125,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-067787 · tm2217555-5_4seq1.xml · derivative · entry 2 Akins Martin P. · CIK 0001655236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of Common Stock, which may be settled in shares of Common Stock or cash, as elected by the Compensation Committee of the Board of Directors of the Company. If the Company's Amended and Restated Stock 2018 Incentive Plan is not approved at the 2022 annual meeting, the restricted stock units will be settled in cash. F3 · kind: On December 31, 2021, the reporting person was granted restricted stock units in accordance with the Company's Amended and Restated Stock 2018 Incentive Plan ("Plan") that were settled in January 2022. The Plan was approved by the stockholders of the Company at the Company's 2021 annual meeting held December 31, 2021. Subsequent to such approval, a lawsuit was filed against the Company alleging that the Company did not properly count the broker non-votes on such matter, and that as a result the Plan was not properly approved at the 2021 annual meeting. The Company decided to re-submit the Plan to its stockholders for re-approvals at its upcoming annual meeting rather than incurring the expense of pursuing litigation. F5 · kind: In connection with the re-submission of the Plan, the delivery of shares under the Plan pursuant to the settlement of restricted stock units granted under the Plan on December 31, 2021 has been rescinded and the amendment and restatement of the 2018 Stock Incentive Plan has been terminated. The restricted stock units will be settled upon re-approval of the amended and restated Plan in either cash or shares of common stock, as will be determined by our Compensation Committee in its sole discretion, which is expected to occur at the 2022 annual meeting. If the Plan is not approved, the restricted stock units will be settled in cash. F2 · price: Each restricted stock unit represents the right to receive, following vesting, one share of Common Stock, which may be settled in shares of Common Stock or cash, as elected by the Compensation Committee of the Board of Directors of the Company. If the Company's Amended and Restated Stock 2018 Incentive Plan is not approved at the 2022 annual meeting, the restricted stock units will be settled in cash. F1 · derivative.exercise_date: On December 31, 2021, following the Company's 2021 annual meeting of stockholders, the reporting person was granted 125,000 restricted stock units as non-employee director equity compensation pursuant to the terms and conditions of the Company's Director Compensation Policy and 2018 Stock Incentive Plan. The restricted stock units vested on January 3, 2022, the first business day of 2022. F1 · derivative.expiration_date: On December 31, 2021, following the Company's 2021 annual meeting of stockholders, the reporting person was granted 125,000 restricted stock units as non-employee director equity compensation pursuant to the terms and conditions of the Company's Director Compensation Policy and 2018 Stock Incentive Plan. The restricted stock units vested on January 3, 2022, the first business day of 2022. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 21:49 UTC | Exela Technologies, Inc. XELA · Entity 76832 | OtherCommon Stock, par value $0.0001 per share | 125,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-067787 · tm2217555-5_4seq1.xml · nonDerivative · entry 1 Akins Martin P. · CIK 0001655236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,984 F3 · kind: On December 31, 2021, the reporting person was granted restricted stock units in accordance with the Company's Amended and Restated Stock 2018 Incentive Plan ("Plan") that were settled in January 2022. The Plan was approved by the stockholders of the Company at the Company's 2021 annual meeting held December 31, 2021. Subsequent to such approval, a lawsuit was filed against the Company alleging that the Company did not properly count the broker non-votes on such matter, and that as a result the Plan was not properly approved at the 2021 annual meeting. The Company decided to re-submit the Plan to its stockholders for re-approvals at its upcoming annual meeting rather than incurring the expense of pursuing litigation. F5 · kind: In connection with the re-submission of the Plan, the delivery of shares under the Plan pursuant to the settlement of restricted stock units granted under the Plan on December 31, 2021 has been rescinded and the amendment and restatement of the 2018 Stock Incentive Plan has been terminated. The restricted stock units will be settled upon re-approval of the amended and restated Plan in either cash or shares of common stock, as will be determined by our Compensation Committee in its sole discretion, which is expected to occur at the 2022 annual meeting. If the Plan is not approved, the restricted stock units will be settled in cash. F3 · price: On December 31, 2021, the reporting person was granted restricted stock units in accordance with the Company's Amended and Restated Stock 2018 Incentive Plan ("Plan") that were settled in January 2022. The Plan was approved by the stockholders of the Company at the Company's 2021 annual meeting held December 31, 2021. Subsequent to such approval, a lawsuit was filed against the Company alleging that the Company did not properly count the broker non-votes on such matter, and that as a result the Plan was not properly approved at the 2021 annual meeting. The Company decided to re-submit the Plan to its stockholders for re-approvals at its upcoming annual meeting rather than incurring the expense of pursuing litigation. F5 · price: In connection with the re-submission of the Plan, the delivery of shares under the Plan pursuant to the settlement of restricted stock units granted under the Plan on December 31, 2021 has been rescinded and the amendment and restatement of the 2018 Stock Incentive Plan has been terminated. The restricted stock units will be settled upon re-approval of the amended and restated Plan in either cash or shares of common stock, as will be determined by our Compensation Committee in its sole discretion, which is expected to occur at the 2022 annual meeting. If the Plan is not approved, the restricted stock units will be settled in cash. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 21:08 UTC | Exela Technologies, Inc. XELA · Entity 76832 | Grant6.00% Series B Cumulative Convertible Perpetual Pref. Stock · Derivative | 1,270 | Not disclosed Strike: $1.25 | Not disclosed |
DisclosureSEC source: 0001104659-22-034110 · tm228645-5_4seq1.xml · derivative · entry 2 Akins Martin P. · CIK 0001655236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,270 Underlying: Common Stock · 25,400 shares Expires not disclosed F1 · derivative.exercise_price: On March 11, 2022, the Issuer completed an offer to exchange shares of its Common Stock for its 6.00% Series B Cumulative Convertible Perpetual Preferred Stock (the "Series B Preferred Stock"), with each 20 shares of Common Stock being exchangeable in the Offer for one share of Series B Preferred Stock having a liquidation preference of $25.00 per share of Series B Preferred Stock (an effective price of $1.25 per share of Common Stock). For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the board of directors of the Issuer approved the transactions contemplated by this Form 4. F2 · derivative.exercise_price: Holders of the Issuer's Series B Preferred Stock have the option to convert some or all of their shares of Series B Preferred Stock initially into shares of Common Stock at a Conversion Price of $1.25 (subject to adjustment in certain events). In addition, if at any time the Five-Day VWAP of the Issuer's Common Stock exceeds the Conversion Price, the Issuer will have the option to convert all outstanding shares of Series B Preferred Stock into shares of Common Stock at the Conversion Price of $1.25. The Series B Preferred Stock has no maturity date. F1 · kind: On March 11, 2022, the Issuer completed an offer to exchange shares of its Common Stock for its 6.00% Series B Cumulative Convertible Perpetual Preferred Stock (the "Series B Preferred Stock"), with each 20 shares of Common Stock being exchangeable in the Offer for one share of Series B Preferred Stock having a liquidation preference of $25.00 per share of Series B Preferred Stock (an effective price of $1.25 per share of Common Stock). For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the board of directors of the Issuer approved the transactions contemplated by this Form 4. F3 · price: A liquidation preference of $25.00 per share of Series B Preferred Stock means an effective price of $1.25 per share of Common Stock tendered in the Offer. F1 · derivative.exercise_date: On March 11, 2022, the Issuer completed an offer to exchange shares of its Common Stock for its 6.00% Series B Cumulative Convertible Perpetual Preferred Stock (the "Series B Preferred Stock"), with each 20 shares of Common Stock being exchangeable in the Offer for one share of Series B Preferred Stock having a liquidation preference of $25.00 per share of Series B Preferred Stock (an effective price of $1.25 per share of Common Stock). For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the board of directors of the Issuer approved the transactions contemplated by this Form 4. F2 · derivative.exercise_date: Holders of the Issuer's Series B Preferred Stock have the option to convert some or all of their shares of Series B Preferred Stock initially into shares of Common Stock at a Conversion Price of $1.25 (subject to adjustment in certain events). In addition, if at any time the Five-Day VWAP of the Issuer's Common Stock exceeds the Conversion Price, the Issuer will have the option to convert all outstanding shares of Series B Preferred Stock into shares of Common Stock at the Conversion Price of $1.25. The Series B Preferred Stock has no maturity date. F1 · derivative.expiration_date: On March 11, 2022, the Issuer completed an offer to exchange shares of its Common Stock for its 6.00% Series B Cumulative Convertible Perpetual Preferred Stock (the "Series B Preferred Stock"), with each 20 shares of Common Stock being exchangeable in the Offer for one share of Series B Preferred Stock having a liquidation preference of $25.00 per share of Series B Preferred Stock (an effective price of $1.25 per share of Common Stock). For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the board of directors of the Issuer approved the transactions contemplated by this Form 4. F2 · derivative.expiration_date: Holders of the Issuer's Series B Preferred Stock have the option to convert some or all of their shares of Series B Preferred Stock initially into shares of Common Stock at a Conversion Price of $1.25 (subject to adjustment in certain events). In addition, if at any time the Five-Day VWAP of the Issuer's Common Stock exceeds the Conversion Price, the Issuer will have the option to convert all outstanding shares of Series B Preferred Stock into shares of Common Stock at the Conversion Price of $1.25. The Series B Preferred Stock has no maturity date. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 21:08 UTC | Exela Technologies, Inc. XELA · Entity 76832 | Disposition to issuerCommon Stock | 25,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-034110 · tm228645-5_4seq1.xml · nonDerivative · entry 1 Akins Martin P. · CIK 0001655236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,984 F1 · price: On March 11, 2022, the Issuer completed an offer to exchange shares of its Common Stock for its 6.00% Series B Cumulative Convertible Perpetual Preferred Stock (the "Series B Preferred Stock"), with each 20 shares of Common Stock being exchangeable in the Offer for one share of Series B Preferred Stock having a liquidation preference of $25.00 per share of Series B Preferred Stock (an effective price of $1.25 per share of Common Stock). For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the board of directors of the Issuer approved the transactions contemplated by this Form 4. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:40 UTC | Exela Technologies, Inc. XELA · Entity 76832 | Exercise / conversionRestricted Stock Units · Derivative | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-001182 · tm221435-1_4seq1.xml · derivative · entry 5 Akins Martin P. · CIK 0001655236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of Common Stock, which may be settled in shares of Common Stock or cash as elected by the Compensation Committee of the Board of Directors of the Company. F4 · derivative.exercise_date: On December 31, 2021, following the Company's 2021 annual meeting of stockholders, the reporting person was granted 125,000 restricted stock units as non-employee director equity compensation for 2021 pursuant to the terms and conditions of the Company's Director Compensation Policy and 2018 Stock Incentive Plan. The restricted stock units vested on January 3, 2022, the first business day of 2022. F4 · derivative.expiration_date: On December 31, 2021, following the Company's 2021 annual meeting of stockholders, the reporting person was granted 125,000 restricted stock units as non-employee director equity compensation for 2021 pursuant to the terms and conditions of the Company's Director Compensation Policy and 2018 Stock Incentive Plan. The restricted stock units vested on January 3, 2022, the first business day of 2022. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:40 UTC | Exela Technologies, Inc. XELA · Entity 76832 | Exercise / conversionCommon Stock | 125,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-001182 · tm221435-1_4seq1.xml · nonDerivative · entry 2 Akins Martin P. · CIK 0001655236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Shares of Common Stock issued upon vesting of restricted stock units will be settled following filing by Exela Technologies Inc. of a Registration Statement on Form S-8 with respect thereto. F1 · price: Each restricted stock unit represents the right to receive, following vesting, one share of Common Stock, which may be settled in shares of Common Stock or cash as elected by the Compensation Committee of the Board of Directors of the Company. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:40 UTC | Exela Technologies, Inc. XELA · Entity 76832 | GrantRestricted Stock Units · Derivative | 125,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-001182 · tm221435-1_4seq1.xml · derivative · entry 4 Akins Martin P. · CIK 0001655236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of Common Stock, which may be settled in shares of Common Stock or cash as elected by the Compensation Committee of the Board of Directors of the Company. F1 · price: Each restricted stock unit represents the right to receive, following vesting, one share of Common Stock, which may be settled in shares of Common Stock or cash as elected by the Compensation Committee of the Board of Directors of the Company. F4 · derivative.exercise_date: On December 31, 2021, following the Company's 2021 annual meeting of stockholders, the reporting person was granted 125,000 restricted stock units as non-employee director equity compensation for 2021 pursuant to the terms and conditions of the Company's Director Compensation Policy and 2018 Stock Incentive Plan. The restricted stock units vested on January 3, 2022, the first business day of 2022. F4 · derivative.expiration_date: On December 31, 2021, following the Company's 2021 annual meeting of stockholders, the reporting person was granted 125,000 restricted stock units as non-employee director equity compensation for 2021 pursuant to the terms and conditions of the Company's Director Compensation Policy and 2018 Stock Incentive Plan. The restricted stock units vested on January 3, 2022, the first business day of 2022. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:40 UTC | Exela Technologies, Inc. XELA · Entity 76832 | Exercise / conversionRestricted Stock Units · Derivative | 13,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-001182 · tm221435-1_4seq1.xml · derivative · entry 3 Akins Martin P. · CIK 0001655236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,227 Underlying: Common Stock · 13,227 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of Common Stock, which may be settled in shares of Common Stock or cash as elected by the Compensation Committee of the Board of Directors of the Company. F2 · derivative.exercise_date: On August 13, 2019, the reporting person was granted 119,047 restricted stock units (before taking into account the one-for-three Reverse Stock Split effected by the Company on January 25, 2021) as non-employee director equity compensation pursuant to the terms and conditions of the Company's Director Compensation Policy and 2018 Stock Incentive Plan. The remainder of this award will vest immediately prior to the 2022 annual meeting of the Company. F2 · derivative.expiration_date: On August 13, 2019, the reporting person was granted 119,047 restricted stock units (before taking into account the one-for-three Reverse Stock Split effected by the Company on January 25, 2021) as non-employee director equity compensation pursuant to the terms and conditions of the Company's Director Compensation Policy and 2018 Stock Incentive Plan. The remainder of this award will vest immediately prior to the 2022 annual meeting of the Company. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:40 UTC | Exela Technologies, Inc. XELA · Entity 76832 | Exercise / conversionCommon Stock, par value $0.0001 per share | 13,227 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-001182 · tm221435-1_4seq1.xml · nonDerivative · entry 1 Akins Martin P. · CIK 0001655236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the right to receive, following vesting, one share of Common Stock, which may be settled in shares of Common Stock or cash as elected by the Compensation Committee of the Board of Directors of the Company. Read SEC document |
| December 09, 2021 Filed Dec 13, 2021 08:15 UTC | Exela Technologies, Inc. XELA · Entity 76832 | GrantCommon Stock, par value $0.0001 per share | 63,492 | $1.26 | $79,999.92 |
DisclosureSEC source: 0001104659-21-148887 · tm2135129-3_4seq1.xml · nonDerivative · entry 1 Akins Martin P. · CIK 0001655236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,157 F1 · price: On December 9, pursuant to the Subscription Agreement by and between Martin P. Akins and Exela Technologies, Inc., Martin P. Akins purchased 63,492 shares of Common Stock for an aggregate purchase price of $80,000. The amount of purchased shares was calculated based on the share price at the close of business on December 8, 2021. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 18:06 UTC | Exela Technologies, Inc. XELA · Entity 76832 | Exercise / conversionRestricted Stock Units · Derivative | 37,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-141057 · tm2039685d1_4.xml · derivative · entry 3 Akins Martin P. · CIK 0001655236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,312 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of Common Stock. F3 · derivative.exercise_date: On August 13, 2019, the reporting person was granted 37,312 restricted stock units as non-employee director equity compensation pursuant to the terms and conditions of the Company's Director Compensation Policy and 2018 Stock Incentive Plan. This award has vested in full and such vested restricted stock units settled for shares of Common Stock. F3 · derivative.expiration_date: On August 13, 2019, the reporting person was granted 37,312 restricted stock units as non-employee director equity compensation pursuant to the terms and conditions of the Company's Director Compensation Policy and 2018 Stock Incentive Plan. This award has vested in full and such vested restricted stock units settled for shares of Common Stock. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 18:06 UTC | Exela Technologies, Inc. XELA · Entity 76832 | Exercise / conversionRestricted Stock Units · Derivative | 39,683 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-141057 · tm2039685d1_4.xml · derivative · entry 2 Akins Martin P. · CIK 0001655236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,364 Underlying: Common Stock · 39,683 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of Common Stock. F2 · derivative.exercise_date: On August 13, 2019, the reporting person was granted 119,047 restricted stock units as non-employee director equity compensation pursuant to the terms and conditions of the Company's Director Compensation Policy and 2018 Stock Incentive Plan. The remainder of this award will vest in equal installments immediately prior to each of the 2021 and 2022 annual meetings of the Company. F2 · derivative.expiration_date: On August 13, 2019, the reporting person was granted 119,047 restricted stock units as non-employee director equity compensation pursuant to the terms and conditions of the Company's Director Compensation Policy and 2018 Stock Incentive Plan. The remainder of this award will vest in equal installments immediately prior to each of the 2021 and 2022 annual meetings of the Company. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 18:06 UTC | Exela Technologies, Inc. XELA · Entity 76832 | Exercise / conversionCommon Stock | 76,995 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-141057 · tm2039685d1_4.xml · nonDerivative · entry 1 Akins Martin P. · CIK 0001655236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the right to receive, following vesting, one share of Common Stock. Read SEC document |
| August 13, 2019 Filed Aug 13, 2019 12:38 UTC | Exela Technologies, Inc. XELA · Entity 76832 | GrantRestricted Stock Units · Derivative | 37,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-045489 · a4.xml · derivative · entry 2 Akins Martin P. · CIK 0001655236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,312 Underlying: Common Stock · 37,312 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of Common Stock. F3 · derivative.exercise_date: On August 13, 2019, the reporting person was granted 37,312 restricted stock units as non-employee director equity compensation pursuant to the terms and conditions of the Company's Director Compensation Policy and 2018 Stock Incentive Plan. This award will vest in full immediately prior to the 2020 annual meeting of the stockholders of the Company. F3 · derivative.expiration_date: On August 13, 2019, the reporting person was granted 37,312 restricted stock units as non-employee director equity compensation pursuant to the terms and conditions of the Company's Director Compensation Policy and 2018 Stock Incentive Plan. This award will vest in full immediately prior to the 2020 annual meeting of the stockholders of the Company. Read SEC document |
| August 13, 2019 Filed Aug 13, 2019 12:38 UTC | Exela Technologies, Inc. XELA · Entity 76832 | GrantRestricted Stock Units · Derivative | 119,047 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-045489 · a4.xml · derivative · entry 1 Akins Martin P. · CIK 0001655236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,047 Underlying: Common Stock · 119,047 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of Common Stock. F2 · derivative.exercise_date: On August 13, 2019, the reporting person was granted 119,047 restricted stock units as non-employee director equity compensation pursuant to the terms and conditions of the Company's Director Compensation Policy and 2018 Stock Incentive Plan. This award will vest in equal installments immediately prior to each of the 2020, 2021 and 2022 annual meetings of the stockholders of the Company. F2 · derivative.expiration_date: On August 13, 2019, the reporting person was granted 119,047 restricted stock units as non-employee director equity compensation pursuant to the terms and conditions of the Company's Director Compensation Policy and 2018 Stock Incentive Plan. This award will vest in equal installments immediately prior to each of the 2020, 2021 and 2022 annual meetings of the stockholders of the Company. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 16:09 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerPhantom Stock Units · Derivative | 460.815 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000950138-18-000665 · edgar.xml · derivative · entry 10 Akins Martin P. · CIK 0001655236 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 460.815 shares Expires not disclosed F4 · security: Phantom Stock Unit credited under the Company's Executive Deferred Compensation Plan. F5 · derivative.exercise_price: Upon distribution, each phantom stock unit would have converted into one share of the Issuer's common stock. F6 · kind: Pursuant to the Merger Agreement, upon closing of the Merger, each phantom stock unit was converted into a stock unit relating to the common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F5 · price: Upon distribution, each phantom stock unit would have converted into one share of the Issuer's common stock. F7 · derivative.exercise_date: Basic Company Credit by the Issuer to Reporting Person's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates. F7 · derivative.expiration_date: Basic Company Credit by the Issuer to Reporting Person's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 16:09 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 47,254 | $0.00 Strike: $67.62 | $0.00 |
DisclosureSEC source: 0000950138-18-000665 · edgar.xml · derivative · entry 9 Akins Martin P. · CIK 0001655236 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 47,254 shares Expires 2027-03-08 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 16:09 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 48,735 | $0.00 Strike: $69.57 | $0.00 |
DisclosureSEC source: 0000950138-18-000665 · edgar.xml · derivative · entry 8 Akins Martin P. · CIK 0001655236 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 48,735 shares Expires 2026-03-09 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 16:09 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 34,909 | $0.00 Strike: $86.82 | $0.00 |
DisclosureSEC source: 0000950138-18-000665 · edgar.xml · derivative · entry 7 Akins Martin P. · CIK 0001655236 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 34,909 shares Expires 2025-12-01 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 16:09 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 5,626 | $0.00 Strike: $84.83 | $0.00 |
DisclosureSEC source: 0000950138-18-000665 · edgar.xml · derivative · entry 6 Akins Martin P. · CIK 0001655236 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 5,626 shares Expires 2025-03-04 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 16:09 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 5,946 | $0.00 Strike: $77.15 | $0.00 |
DisclosureSEC source: 0000950138-18-000665 · edgar.xml · derivative · entry 5 Akins Martin P. · CIK 0001655236 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 5,946 shares Expires 2021-03-05 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 16:09 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 4,280 | $0.00 Strike: $58.17 | $0.00 |
DisclosureSEC source: 0000950138-18-000665 · edgar.xml · derivative · entry 4 Akins Martin P. · CIK 0001655236 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 4,280 shares Expires 2020-03-06 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 16:09 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 1,547 | $0.00 Strike: $53.54 | $0.00 |
DisclosureSEC source: 0000950138-18-000665 · edgar.xml · derivative · entry 3 Akins Martin P. · CIK 0001655236 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 1,547 shares Expires 2019-05-15 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 16:09 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 1,964 | $0.00 Strike: $53.05 | $0.00 |
DisclosureSEC source: 0000950138-18-000665 · edgar.xml · derivative · entry 2 Akins Martin P. · CIK 0001655236 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 1,964 shares Expires 2019-02-27 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 16:09 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerCommon Stock | 46,219.16 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000665 · edgar.xml · nonDerivative · entry 1 Akins Martin P. · CIK 0001655236 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a unit with respect to common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 30, 2018 Filed Dec 4, 2018 17:18 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Tax withholdingCommon Stock | 1,043 | $101.47 | $105,833.21 |
DisclosureSEC source: 0000950138-18-000641 · edgar.xml · nonDerivative · entry 2 Akins Martin P. · CIK 0001655236 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,219.16 F1 · shares: Represents shares tendered to Company to cover Reporting Person's tax liability due upon vesting of restricted stock units previously awarded under long-term incentive plans. Read SEC document |
| November 05, 2018 Filed Dec 4, 2018 17:18 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | GiftCommon Stock | 1,721 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000641 · edgar.xml · nonDerivative · entry 1 Akins Martin P. · CIK 0001655236 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,262.16 Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 18:36 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Tax withholdingCommon Stock | 2,950 | $74.58 | $220,011.00 |
DisclosureSEC source: 0000950138-18-000242 · edgar.xml · nonDerivative · entry 3 Akins Martin P. · CIK 0001655236 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,983.16 F3 · shares: Represents shares tendered to Company to cover Reporting Person's tax liability due upon vesting of performance shares. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 18:36 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | GrantCommon Stock | 8,637 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000242 · edgar.xml · nonDerivative · entry 2 Akins Martin P. · CIK 0001655236 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,933.16 F2 · price: Vesting of performance shares granted under Express Scripts, Inc. 2011 Long-Term Incentive Plan. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 18:36 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | GrantCommon Stock | 16,720 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000242 · edgar.xml · nonDerivative · entry 1 Akins Martin P. · CIK 0001655236 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,296.16 F1 · price: Grant of restricted stock units pursuant to Express Scripts Holding Company 2016 Long-Term Incentive Plan. Awards vest in three equal installments on February 28, 2019, February 28, 2020, and February 28, 2021. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 16:51 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Tax withholdingCommon Stock | 965 | $75.45 | $72,809.25 |
DisclosureSEC source: 0000950138-18-000206 · edgar.xml · nonDerivative · entry 1 Akins Martin P. · CIK 0001655236 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,576.16 F1 · shares: Represents shares tendered to Company to cover Reporting Person's tax liability due upon vesting of restricted stock units previously awarded under long-term incentive plans. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 16:07 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | GrantPhantom Stock Unit · Derivative | 219.1717 | $78.10 Strike: $0.00 | $17,117.31 |
DisclosureSEC source: 0000950138-18-000087 · edgar.xml · derivative · entry 1 Akins Martin P. · CIK 0001655236 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460.815 Underlying: Express Scripts Holding Company Common Stock · 219.1717 shares Expires not disclosed F1 · security: Phantom Stock Unit credited under the Company's Executive Deferred Compensation Plan. F2 · derivative.exercise_price: Upon distribution each Phantom Stock Unit converts to one share of the Company's Common Stock. F3 · derivative.exercise_date: Basic Company Credit by Express Scripts Holding Company to Participant's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates. F3 · derivative.expiration_date: Basic Company Credit by Express Scripts Holding Company to Participant's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 16:47 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Tax withholdingCommon Stock | 769 | $64.41 | $49,531.29 |
DisclosureSEC source: 0000950138-17-000780 · edgar.xml · nonDerivative · entry 1 Akins Martin P. · CIK 0001655236 · Sr. VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,541.16 F1 · shares: Represents shares tendered to Company to cover Reporting Person's tax liability due upon vesting of restricted stock units previously awarded under long-term incentive plans. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 16:02 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | GrantNon-Qualified Stock Option (Right-to-Buy) · Derivative | 47,254 | Not disclosed Strike: $67.62 | Not disclosed |
DisclosureSEC source: 0000950138-17-000305 · edgar.xml · derivative · entry 2 Akins Martin P. · CIK 0001655236 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,254 Underlying: Express Scripts Holding Company Common Stock · 47,254 shares Expires 2027-03-08 F2 · price: Grant of stock option pursuant to Express Scripts Holding Company 2016 Long-Term Incentive Plan. Vests in three equal installments on February 28, 2018, February 28, 2019, and February 28, 2020. F2 · derivative.exercise_date: Grant of stock option pursuant to Express Scripts Holding Company 2016 Long-Term Incentive Plan. Vests in three equal installments on February 28, 2018, February 28, 2019, and February 28, 2020. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 16:02 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | GrantCommon Stock | 9,859 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-17-000305 · edgar.xml · nonDerivative · entry 1 Akins Martin P. · CIK 0001655236 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,310.16 F1 · price: Grant of restricted stock units pursuant to Express Scripts Holding Company 2016 Long-Term Incentive Plan. Awards vest in three equal installments on February 28, 2018, February 28, 2019, and February 28, 2020. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 16:31 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Tax withholdingCommon Stock | 1,373 | $70.65 | $97,002.45 |
DisclosureSEC source: 0000950138-17-000228 · edgar.xml · nonDerivative · entry 1 Akins Martin P. · CIK 0001655236 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,451.16 F1 · shares: Represents shares tendered to Company to cover Reporting Person's tax liability due upon vesting of restricted stock units previously awarded under long-term incentive plans. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 16:01 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | GrantPhantom Stock Unit · Derivative | 209.1881 | $69.11 Strike: $0.00 | $14,456.99 |
DisclosureSEC source: 0000950138-17-000097 · edgar.xml · derivative · entry 1 Akins Martin P. · CIK 0001655236 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241.6433 Underlying: Express Scripts Holding Company Common Stock · 209.1881 shares Expires not disclosed F1 · security: Phantom Stock Unit credited under the Company's Executive Deferred Compensation Plan. F2 · derivative.exercise_price: Upon distribution each Phantom Stock Unit converts to one share of the Company's Common Stock. F3 · derivative.exercise_date: Basic Company Credit by Express Scripts Holding Company to Participant's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates. F3 · derivative.expiration_date: Basic Company Credit by Express Scripts Holding Company to Participant's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 16:06 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Tax withholdingCommon Stock | 769 | $75.83 | $58,313.27 |
DisclosureSEC source: 0000950138-16-001486 · edgar.xml · nonDerivative · entry 1 Akins Martin P. · CIK 0001655236 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,824.16 F1 · shares: Represents shares tendered to Company to cover Reporting Person's tax liability due upon vesting of restricted stock units previously awarded under long-term incentive plans. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.